KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers--
Previous
Previous
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
Next
Next
